DYN icon

Dyne Therapeutics

23.97 USD
+0.06
0.25%
At close Dec 24, 4:00 PM EST
After hours
24.49
+0.52
2.17%
1 day
0.25%
5 days
-10.19%
1 month
-18.61%
3 months
-28.23%
6 months
-32.73%
Year to date
83.54%
1 year
89.49%
5 years
0.29%
10 years
0.29%
 

About: Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

Employees: 173

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 55

22% more call options, than puts

Call options by funds: $10.7M | Put options by funds: $8.75M

20% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 35

4% more funds holding

Funds holding: 194 [Q2] → 201 (+7) [Q3]

1% more capital invested

Capital invested by funds: $3.96B [Q2] → $4.02B (+$56.6M) [Q3]

3.14% less ownership

Funds ownership: 114.7% [Q2] → 111.56% (-3.14%) [Q3]

29% less funds holding in top 10

Funds holding in top 10: 14 [Q2] → 10 (-4) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$35
46%
upside
Avg. target
$46
93%
upside
High target
$55
129%
upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
Baird
Brian Skorney
21% 1-year accuracy
5 / 24 met price target
92%upside
$46
Outperform
Initiated
13 Dec 2024
RBC Capital
Luca Issi
23% 1-year accuracy
13 / 56 met price target
88%upside
$45
Outperform
Initiated
26 Nov 2024
Chardan Capital
Keay Nakae
31% 1-year accuracy
22 / 72 met price target
109%upside
$50
Buy
Maintained
13 Nov 2024
HC Wainwright & Co.
Andrew Fein
31% 1-year accuracy
102 / 328 met price target
129%upside
$55
Buy
Reiterated
13 Nov 2024
JP Morgan
Tessa Romero
22% 1-year accuracy
4 / 18 met price target
46%upside
$35
Neutral
Downgraded
24 Oct 2024

Financial journalist opinion

Positive
Proactive Investors
1 week ago
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The FDA earlier this month published the draft guidance on its policies and procedures for the accelerated approval (AA) pathway for drugs for serious conditions that fulfil an unmet medical need.
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
Positive
Seeking Alpha
1 month ago
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significant improvement over Sarepta's Eteplirsen in Phase 1/2 trials, potentially accelerating approval and boosting DYN's stock. Key risks include executive reshuffling and potential hidden issues with IP, but current data and market potential make DYN attractive for speculative investors.
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Neutral
GlobeNewsWire
1 month ago
Dyne Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.  (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following upcoming investor conferences:
Dyne Therapeutics to Present at Upcoming Investor Conferences
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Neutral
Accesswire
1 month ago
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Possible Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Possible Securities Law Violations
Neutral
Accesswire
1 month ago
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
Neutral
PRNewsWire
1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Neutral
Accesswire
1 month ago
The Schall Law Firm Encourages Investor Participation In A Case Against Dyne Therapeutics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investor Participation In A Case Against Dyne Therapeutics, Inc. For Securities Law Violations
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Neutral
Accesswire
1 month ago
Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Charts implemented using Lightweight Charts™